The USPTO granted Patent US12589064B2 to Caregen Co., Ltd. for a Trolox-peptide conjugate with hair loss prevention applications. The patent (Application No. 17607115, filed May 6, 2020) claims a compound where Trolox and a peptide are chemically bonded, effective at inhibiting 5α-reductase, preventing cell death, promoting growth, and providing antioxidant activity. The grant confers exclusive intellectual property rights to the assignee.

Regulated entities do not need to take immediate compliance actions based on this patent grant. However, pharmaceutical and biotechnology companies developing hair loss treatments or 5α-reductase inhibitors should review this patent to assess potential freedom-to-operate concerns. Companies should ensure their R&D activities do not infringe on the granted claims and should consult with IP counsel regarding licensing opportunities if commercializing related products.